Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?
Publication
, Journal Article
Madueke, I; Abern, MR
Published in: Oncology (Williston Park)
June 19, 2019
Duke Scholars
Published In
Oncology (Williston Park)
ISSN
0890-9091
Publication Date
June 19, 2019
Volume
33
Issue
6
Start / End Page
235 / 242
Location
United States
Related Subject Headings
- Watchful Waiting
- Risk Assessment
- Prostatic Neoplasms
- Prognosis
- Population Surveillance
- Neoplasm Grading
- Molecular Imaging
- Male
- Humans
- Gene Expression Profiling
Citation
APA
Chicago
ICMJE
MLA
NLM
Madueke, I., & Abern, M. R. (2019). Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer? Oncology (Williston Park), 33(6), 235–242.
Madueke, Ikenna, and Michael R. Abern. “Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?” Oncology (Williston Park) 33, no. 6 (June 19, 2019): 235–42.
Madueke I, Abern MR. Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer? Oncology (Williston Park). 2019 Jun 19;33(6):235–42.
Madueke, Ikenna, and Michael R. Abern. “Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?” Oncology (Williston Park), vol. 33, no. 6, June 2019, pp. 235–42.
Madueke I, Abern MR. Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer? Oncology (Williston Park). 2019 Jun 19;33(6):235–242.
Published In
Oncology (Williston Park)
ISSN
0890-9091
Publication Date
June 19, 2019
Volume
33
Issue
6
Start / End Page
235 / 242
Location
United States
Related Subject Headings
- Watchful Waiting
- Risk Assessment
- Prostatic Neoplasms
- Prognosis
- Population Surveillance
- Neoplasm Grading
- Molecular Imaging
- Male
- Humans
- Gene Expression Profiling